IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing - BioSpace

20 Aug 2020 - BioSpace

sgx:594 sgx:o6z

---

Lonza in manufacturing deal with Moderna for Covid-19 vaccine

1 May 2020 - The Edge Markets
SINGAPOR (May 1): Swiss pharmaceutical company Lonza Group, which has a secondary listing on SGX, has announced a ten-year deal with US-based Moderna to undertake large scale manufacturing of the latter’s mRNA-1273, which is a vaccine that is being tested for use against the novel coronavirus. Under ...
sgx:o6z sgx:s68

---

Lonza's core profits rose 9.5% to $720.6m in H1

25 Jul 2019 - Singapore Business Review
Its pharma biotech & nutrition segment recorded 10.8% sales growth. Swiss biotech and pharma company Lonza saw profits climb 9.5% YoY to $720.6m (CHF520m) in H1 2019 from $658.2m (CHF475m) in 2018, an SGX filing revealed. Its total sales went up 6.4% YoY to $4.12b (CHF2.98b) from $3.87b (CHF2.8b) in ...
sgx:o6z

---

Lonza: Reports A Strong Third Quarter & Capsugel Integration On Track.

26 Oct 2017 - ShareInvestor Express
Continued strong performance in Q3 2017 for Lonza standalone as expected. Both segments on track to deliver full-year targets with offerings along the healthcare continuum adding to the other growth drivers. Outlook 2017 for Lonza standalone, which was already upgraded in April 2017, is confirmed. Capsugel ...
sgx:o6z

---

Lonza: Acquires Micro-Macinazione To Create The Global Leader In Micronization Capacity And Capabilities.

4 Aug 2017 - ShareInvestor Express
Lonza has acquired Micro-Macinazione, one of Europe's leading contract manufacturers providing micronization of active ingredients for the pharmaceutical and fine chemical industries. Micro-Macinazione, which had sales of ~ CHF 20 million in 2016, has 120 employees and is based in Monteggio, Switzerland. ...
sgx:o6z

---

Lonza: Prices EUR700 Million & USD200 Million Multi Tranche "Schuldschein" Loan.

4 Aug 2017 - ShareInvestor Express
Lonza Group Ltd announced the pricing of its multi-tranche "Schuldschein" loan with a total size of EUR 700 million and USD 200 million at competitive market terms. The EUR tranches have maturities of 4 and 6 years respectively with fixed and variable coupons. The USD tranches have maturities of 5 (variable ...
sgx:o6z

---

Lonza: Completes Acquisition Of Capsugel To Create Leading Integrated Solutions Provider To The Global Pharma & Consumer Healthcare Industries.

6 Jul 2017 - ShareInvestor Express
Acquisition aligns closely with Lonza's strategy to accelerate Lonza's growth and ability to deliver value along the healthcare continuum. Transaction price of USD 5.5 billion, including refinancing of existing Capsugel debt of approximately USD 2 billion...
sgx:o6z

---

Lonza: Prices CHF235 Million Dual Tranche Straight Bonds.

15 Jun 2017 - ShareInvestor Express
Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel, announced the pricing of its dual tranche CHF 235 million straight bonds. The bonds have a maturity of 4 and 7 years respectively with coupons of 0.200% and 0.700%...
sgx:o6z

---

Lonza: Launches Rights Offering.

26 Apr 2017 - ShareInvestor Express
Lonza announced that the Board of Directors determined the final terms of the capital increase by way of a rights offering...
sgx:o6z

---

Lonza: Announces Results Of The 2017 Annual General Meeting, All Motions Proposed By Board Of Directors Accepted.

26 Apr 2017 - ShareInvestor Express
235 shareholders attended, representing 59.96% of the share capital. Shareholders re-elected all existing members of the Board of Directors except for Thomas Ebeling, who did not stand for re-election, and approved the new election of Albert M. Baehny. Rolf Soiron was re-elected as Board Chairperson ...
sgx:o6z

---